Dana Whitfield I hope the expanded use leads to better access overall, though real-world results and side effect management will matter just as much as the trial numbers.
Sam Okafor DeepSeek's 500 billion yuan valuation before IPO looks aggressive given the chip spending, but the CFO hire should help steady investor talks.